Matinas BioPharma Holdings (MTNB) Net Cash Flow (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Net Cash Flow data on file, last reported at -$1.6 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$1.6 million, down 344.72% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.8 million (down 182.8% YoY), and the FY2025 annual result was -$3.3 million, down 231.56% from the prior year.
• Net Cash Flow slipped to -$1.6 million in Q1 2026 per MTNB's latest filing, from -$1.4 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $6.1 million in Q3 2024 and troughed at -$8.9 million in Q2 2022.
• A 5-year average of -$1.1 million and a median of -$1.4 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow plunged 529.34% in 2023, then soared 282.22% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$4.3 million in 2022, then surged by 62.72% to -$1.6 million in 2023, then sank by 85.86% to -$3.0 million in 2024, then soared by 52.31% to -$1.4 million in 2025, then decreased by 11.49% to -$1.6 million in 2026.
• Business Quant data shows MTNB's Net Cash Flow at -$1.6 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.4 million in Q3 2025.